Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET/CT in treatment planning

World Journal of Surgical Oncology

Masahide Ohmichi³  Chihiro Watanabe¹  Hideto Senzaki⁶  Masao Toyoda⁵  Terue Okamura⁴  Koji Kumagai² 

[1] Department of Pathology, Takatsuki Red Cross Hospital, Takatsuki-city, Osaka 569-1096, Japan;Department of Gynecology, Osaka Railway Hospital, 2-22, Matsuzakicho 1-chome, Abeno-ku, Osaka-city, Osaka 545-0053, Japan;Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka 569-1096, Japan;PET Center, Osaka Saiseikai Nakatsu Hospital, Osaka-city, Osaka 530-0012, Japan;Department of Surgery, Osaka Saiseikai Nakatsu Hospital, Osaka-city, Osaka 530-0012, Japan;Department of Pathology, Osaka Saiseikai Nakatsu Hospital, Osaka-city, Osaka 530-0012, Japan

关键词: Treatment planning;    ¹⁸F-FDG PET/CT;    Pararectal lymph node;    Mesorectal lymph node;    Recurrent ovarian carcinoma;   

Others  :  823495
DOI  :  10.1186/1477-7819-11-184

 received in 2013-01-25, accepted in 2013-07-27,  发布年份 2013

【 摘 要 】

Although uncommon, ovarian cancer cells may spread to the rectal lymph nodes. However, few reports have described how to detect and treat such metastases. We report a case of a 59-year-old woman with mesorectal and pararectal lymph node metastases in recurrent ovarian carcinoma, detected conclusively using ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT), and treated by low anterior resection with total mesorectal excision aiming for macroscopic complete resection. The treatment goals for the patient were gradually changed from curative to palliative chemotherapy; she survived for 45 months without rectal obstruction after secondary debulking surgery, and was followed up until autopsy. Thus, ¹⁸F-FDG PET/CT may be valuable for detecting rectal lymph node metastasis and can play an essential role in planning treatment for recurrent ovarian carcinoma.

【 授权许可】

   
2013 Kumagai et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Güth U, Huang DJ, Bauer G, Stieger M, Wight E, Singer G: Metastatic patterns at autopsy in patients with ovarian carcinoma. Cancer 2007, 110:1272-1280.
• [2]Bristow RE, Karlan BY, Chi DS: Surgery for Ovarian Cancer: Principles and Practice. 2nd edition. New York: Informa Healthcare; 2010.
• [3]Richter R, Feyerabend T: Normal Lymph Node Topography: CT Atlas. Berlin: Springer; 2004.
• [4]Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE: Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol 2007, 14:3552-3557.
• [5]Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes AN, Cunha IW, Soares FA: Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol 2011, 104:250-254.
• [6]Galandiuk S, Chaturvedi K, Topor B: Rectal cancer: a compartmental disease, the mesorectum and mesorectal lymph nodes. Recent Results Cancer Res 2005, 165:21-29.
• [7]McMahon CJ, Rofsky NM, Pedrosa I: Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology 2010, 254:31-46.
• [8]Manci N, Bellati F, Graziano M, Pernice M, Muzii L, Angioli R, Benedetti Panici P: Ovarian cancer, diagnosed with PET, with bilateral inguinal lymphadenopathy as primary presenting sign. Gynecol Oncol 2006, 100:621-622.
• [9]Susini T, Olivieri S, Molino C, Castiglione F, Tavella K, Viligiardi R: Ovarian cancer initially presenting as intramammary metastases and mimicking a primary breast carcinoma: a case report and literature review. J Womens Health 2010, 19:169-174.
• [10]Lenhard MS, Burges A, Johnson TR, Stieber P, Kümper C, Ditsch N, Linke R, Friese K: PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Res 2008, 28:2303-2308.
• [11]Prakash P, Cronin CG, Blake MA: Role of PET/CT in ovarian cancer. AJR Am J Roentogenol 2010, 194:W464-470.
• [12]Shreve P, Townsend DW: Clinical PET-CT in Radiology: Integrated Imaging in Oncology. New York: Springer; 2010.
• [13]Park JY, Seo SS, Kang S, Lee KB, Lim SY, Choi HS, Park SY: The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol 2006, 103:977-984.
• [14]Schillaci O: Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med 2012, 42:267-280.
• [15]Chan WL, Ramsay SC, Szeto ER, Freund J, Pohlen JM, Tarlinton LC, Young A, Hickey A, Dura RJ: Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy. Med Imaging Radiat Oncol 2011, 55:379-390.
• [16]Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 2006, 106:1933-1939.